Showing 2161-2170 of 2314 results for "".
- Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-pharmaceuticals-announces-interim-results-from-its-phase-1b-clinical-trial-of-akb-9778-for-primary-open-angle-glaucoma/2476991/Aerpio Pharmaceuticals announced interim results from its phase 1b clinical trial of a topical ocular formulation of AKB-9778 in development as a potential treatment for primary open angle glaucoma (POAG). The phase 1b study is an ongoing randomized, double-masked study designed to assess
- On World Sight Day, Allergan Launches National Campaign to Raise Awareness of Glaucomahttps://modernod.com/news/on-world-sight-day-allergan-launches-national-campaign-to-raise-awareness-of-glaucoma/2476984/Allergan announced a national education campaign called “My Glaucoma.” The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment
- Study Reports High Sensitivity in Diabetic Retinopathy Screening Using Smartphones and Automated-AI in Primary-Carehttps://modernod.com/news/study-reports-high-sensitivity-in-diabetic-retinopathy-screening-using-smartphones-and-automated-ai-in-primary-care/2476982/Nearly 50% of patients with diabetes fail to get an annual eye examination done even in the US and Europe. In many countries, less than 10% of patients referred to ophthalmologists by their primary-care physicians actually complete a dilated retinal examination. Technology can play a role in empo
- LLamasoft Partners with Global Eye Bank, Eversighthttps://modernod.com/news/llamasoft-partners-with-global-eye-bank-eversight/2476974/LLamasoft has announced its partnership with Eversight, a nonprofit organization dedicated to restoring sight and preventing blindness through eye donation, corneal transplantation, and vision research. Eversight will utilize LLamasoft’s solutions to make data-driven decisions that more accuratel
- ProQR Announces Positive Topline Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patientshttps://modernod.com/news/proqr-announces-positive-topline-results-from-the-phase-1-2-study-of-sepofarsen-in-lca10-patients/2476975/ProQR Therapeutics announced positive topline results from the PQ-110-001 study, a phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. “We reported toda
- Navilas at AAO 2019: Laser is Back with Digital Guidance for Posterior Segment Treatmentshttps://modernod.com/news/navilas-at-aao-2019-laser-is-back-with-digital-guidance-for-posterior-segment-treatments/2476955/At this week’s AAO in San Francisco, OD-OS will be showcasing its Navilas 577s laser platform. The Navilas 577s is a retina laser with integrated eye tracking technology, a transparent workflow, and documentation which proves in clinics and teaching hospitals to be the next generation digital las
- Topline Results From Phase 2 Trial Show Nicox’s Glaucoma Drug Candidate NCX 470 Meets Primary Endpointhttps://modernod.com/news/topline-results-from-phase-2-trial-show-nicoxs-glaucoma-drug-candidate-ncx-470-meets-primary-endpoint/2476931/Nicox SA announced positive topline results from its US multicenter, Dolomites dose-response phase 2 clinical trial evaluating investigational NCX 470, a novel second-generation nitric oxide (NO)-donating bimatoprost analog, compared to latanoprost ophthalmic solution 0.005% in 433 patients with
- Nicox Completes Enrollment of NCX 4251 Phase 2 Trial with Topline Results on Track for Q4 2019https://modernod.com/news/nicox-completes-enrolment-of-ncx-4251-phase-2-trial-with-top-line-results-on-track-for-q4-2019/2476918/Nicox SA announced that it has completed enrollment in its multicenter, dose escalating, US phase 2 clinical trial evaluating the safety and tolerability of NCX 4251 in acute exacerbations of blepharitis. The primary objective of this
- Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Boardhttps://modernod.com/news/oculis-announces-appointment-of-leading-ophthalmology-specialists-to-scientific-advisory-board/2476888/Oculis SA announced the appointments of Eric Donnenfeld, MD, and Pr. Ramin Tadayoni, MD, PhD, to its Scientific Advisory Board (SAB). “I am pleased to welcome Eric and Ramin to our SAB and look forward to their contributions as we focus on our objective of developing topical medicines that
- PECAA and Medical Eyeglass Center Announce Partnershiphttps://modernod.com/news/pecaa-and-medical-eyeglass-center-announce-partnership/2476885/PECAA, a nationwide Doctor Alliance Group currently serving over 3,700 independent eye care practitioners, announced that it has entered into a strategic partnership with Medical Eyeglass Center (MEC), an optical disp